Back to IRWDView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Irritable Bowel Syndrome Characterized by Constipation
View Full LandscapeDrug Information
Target Indication
Irritable Bowel Syndrome Characterized by Constipation
Clinical Trial
NCT00948818Last updated: 9/23/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Linaclotide 145 microgramsPhase 3
Opioid-Induced Constipation
LinaclotidePhase 3
Irritable Bowel Syndrome With Constipation
IW-3718Phase 3
Gastroesophageal Reflux Disease (GERD)
Linaclotide AcetatePhase 2
Irritable Bowel Syndrome With Constipation
MD-7246Phase 2
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts